RxDoctor Payments Data

Phillip Amodeo, MD

Neurology · Brunswick, GANPI 1609064146

Payments from drug & device makers

$32,586in general payments, 2019–2025

Across 713 payments — averaging $45.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$21K
  • UCB, Inc.$679
  • Lundbeck LLC$608
  • AstraZeneca$608
  • Pfizer$573
  • Novartis$562
  • plus $8K from 53 others

What the payments were for

  • Speaking & faculty fees$19,50560%
  • Travel & lodging$2301%
  • Food & beverage$12,78039%
  • Education$720%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)127$21,414
UCB, Inc.33$679
Lundbeck LLC32$608
AstraZeneca25$608
Pfizer40$573
Novartis30$562
Argenx US, Inc.18$447
CSL Behring18$437
Adamas Pharmaceuticals, Inc.26$428
EMD Serono, Inc.21$405
Genentech USA, Inc.21$392
Amgen(2 entities)21$377
SK Life Science, Inc.16$369
Lilly USA, LLC19$362
Teva Pharmaceuticals USA, Inc.26$314
Biogen15$310
Acadia Pharmaceuticals Inc16$309
Eisai Inc.18$304
Kyowa Kirin, Inc.17$303
Avanir Pharmaceuticals, Inc.16$254
TG Therapeutics, Inc.8$237
Otsuka America Pharmaceutical, Inc.12$213
Mallinckrodt Hospital Products Inc.11$212
Neurelis, Inc.11$200
Grifols USA, LLC10$180
Sumitomo Pharma America, Inc.9$167
Tanabe Pharma America, Inc.9$162
Neurocrine Biosciences, Inc.8$158
Biohaven Pharmaceuticals, Inc.6$122
Sanofi7$119
Johnson & Johnson(2 entities)5$111
Biohaven Pharmaceutical Holding Company Ltd.6$110
Supernus Pharmaceuticals, Inc.6$90
Sunovion Pharmaceuticals Inc.7$90
Jazz Pharmaceuticals Inc.4$86
Amneal Pharmaceuticals LLC3$81
Impel Pharmaceuticals Inc.4$74
Catalyst Pharmaceuticals, Inc.3$72
Merz Pharmaceuticals, LLC2$65
Acorda Therapeutics, Inc3$55
Abbott1$49
Upsher-smith Laboratories LLC2$48
Vanda Pharmaceuticals Inc.2$43
GE HealthCare1$42
Immedica Pharma US, Inc.2$35
Medtronic2$34
Amylyx Pharmaceuticals, Inc.1$33
Alnylam Pharmaceuticals Inc.2$28
Averitas Pharma Inc.1$24
ANI Pharmaceuticals, Inc.1$24
Mallinckrodt Enterprises LLC1$23
Azurity Pharmaceuticals, Inc.1$22
Aprecia Pharmaceuticals, LLC1$22
E.r. Squibb & Sons, L.L.C.1$20
Portola Pharmaceuticals, LLC1$19
Arbor Pharmaceuticals, Inc.1$16
Avion Pharmaceuticals1$15
Zyla Life Sciences, Inc.1$14
Livanova USA, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,586 in reported general payments places this provider in the 80th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$169,352
Medicare patients
401
Services billed
7,547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole71$102,380
UbrelvyUbrogepant39$54,736
Emgality PenGalcanezumab-Gnlm36$34,999
NuedextaDextromethorphan Hbr/Quinidine21$32,023
Aimovig AutoinjectorErenumab-Aooe30$23,335
BotoxOnabotulinumtoxina16$19,950
QuliptaAtogepant14$14,586
Emgality SyringeGalcanezumab-Gnlm13$10,954
Levetiracetam263$7,032
EliquisApixaban11$6,246
Topiramate ErTopiramate11$5,288
Primidone206$5,243
Lacosamide50$4,187
Carbidopa-LevodopaCarbidopa/Levodopa119$4,134
Memantine Hcl123$3,368

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$213$102,38071 claims
AbbVieUbrelvy, Botox, Qulipta$21,414$89,27269 claims
Avanir Pharmaceuticals, Inc.Nuedexta$254$32,02321 claims
PfizerEliquis$573$6,24611 claims
Upsher-smith Laboratories LLCTopiramate$48$623129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 506 neurology providers in Georgia.

Other neurology in Brunswick

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →